Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Amid Slow Uptake, Sysmex Pitching Its Genomic Profiling via Close Communications with Hospitals, Govt: Exec
September 27, 2019
- Takeda’s TAK-620 Shows Antiviral Activities for CMV Infection in PII
September 26, 2019
- Biogen Japan Chairman Torii to Resign Sept. 30
September 26, 2019
- Chugai’s Comprehensive Genomic Profiling Test Approved for Companion Diagnostic for Lynparza
September 26, 2019
- Mylan EPD Submits Clinical Trial Application in Japan for PIII Study of Eyedrop Therapy for Cystinosis
September 26, 2019
- Chinese Regulators Accept Tenelia for Review
September 25, 2019
- Astellas’ AML Drug Gets European Panel Backing
September 25, 2019
- Mylan to Distribute Eisai’s Cancer Treatment Halaven under Brand Name of Teceris in India
September 24, 2019
- Kyoto Univ. Spinout Boots Up to Develop iPSC-Based Kidney Therapy
September 24, 2019
- Mitsubishi Tanabe to Join Promotion for Santen’s Alesion Eye Drops
September 24, 2019
- Kissei Kicks Off Japan PIII for ITP Drug Fostamatinib
September 24, 2019
- SanBio’s Lead Cell Therapy Rides High with FDA’s RMAT Designation for Traumatic Brain Injury
September 20, 2019
- JCR Drops Temcell Submission for Epidermolysis Bullosa
September 20, 2019
- Kyowa Kirin to Keep Challenging to Boost Global Footprint: President
September 20, 2019
- Japan’s 1st Forteo Biosimilar Nears Market, Mochida Looks at Billion-Yen Sales
September 19, 2019
- US FDA Gives 1st Nod for Lenvima/Keytruda Combo as 2nd-Line Therapy for Endometrial Carcinoma
September 19, 2019
- GSK Launches Clinical Research of Platform for Prevention of COPD Exacerbations
September 19, 2019
- Luring Big Pharma with GPCR Work, Sosei Heptares Treads Its Own Path to Pursue Small Molecule Targets
September 18, 2019
- No Major Impact on Shionogi, Eisai from Purdue’s Bankruptcy Filing
September 18, 2019
- Fujifilm Grabs Rights to Cynata’s Cell Therapy for GVHD
September 18, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…